Near‐normalization of glycaemic control with glucagon‐like peptide‐1 receptor agonist treatment combined with exercise in patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Aims: To investigate the effects of exercise in combination with a glucagon‐like peptide‐1 receptor agonist ( GLP‐1RA ), liraglutide, or placebo for the treatment of type 2 diabetes. Methods: Thirty‐three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of either exercise and liraglutide or exercise and placebo. Both groups had three supervised 60‐minute training sessions per week including spinning and resistance training. Results: Glycated haemoglobin ( HbA1c ) levels dropped by a mean ± standard deviation of 2.0% ± 1.2% (from 8.2% ± 1.4%) in the exercise plus liraglutide group vs 0.3% ± 0.9% (from 8.0% ± 1.2%) in the exercise plus placebo group ( P < .001), and body weight was reduced more with liraglutide (−3.4 ± 2.9 kg vs −1.6 ± 2.3 kg; P < .001). Compared with baseline, similar reductions were seen in body fat (exercise plus liraglutide: −2.5% ± 1.4% [ P < .001]; exercise plus placebo: −2.2% ± 1.9% [ P < .001]) and similar increases were observed in maximum oxygen uptake (exercise plus liraglutide: 0.5 ± 0.5 L O 2 /min [ P < .001]; exercise plus placebo: 0.4 ± 0.4 L O 2 /min [ P = .002]). Greater reductions in fasting plasma glucose (−3.4 ± 2.3 mM vs −0.3 ± 2.6 mM , P < .001) and systolic blood pressure (−5.4 ± 7.4 mm Hg vs −0.6 ± 11.1 mm Hg , P < .01) were seen with exercise plus liraglutide vs exercise plus placebo. The two groups experienced similar increases in quality of life during the intervention. Conclusions: In obese patients with type 2 diabetes, exercise combined with GLP‐1RA treatment near‐normalized HbA1c levels and caused a robust weight loss when compared with placebo. These results suggest that a combination of exercise and GLP‐1RA treatment is effective in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Boulé, N. G., Haddad, E., Kenny, G. P., Wells, G. A., & Sigal, R. J. (2001) · JAMA · doi:10.1001/jama.286.10.1218 · Cited by 1,889
Åstrand, P. O., & Ryhming, I. (1954) · Journal of Applied Physiology · doi:10.1152/jappl.1954.7.2.218 · Cited by 1,558
Umpierre, D. (2011) · JAMA · doi:10.1001/jama.2011.576 · Cited by 1,358 · cited 1×
“6% after increasing the level of physical activity, it is often not sufficient to normalize glycaemic control in patients with type 2 diabetes.(2,8,9) Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from enteroendocrine L cells located in the distal jejunum and ileum in response to meal ingestion.”
BackgroundVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 3×
“Since 2006, GLP-1 receptor agonists (GLP-1RAs) have been used for the treatment of patients with type 2 diabetes.(11) Liraglutide is a once-daily administered GLP-1RA with beneficial effects on HbA1c levels, body weight and body composition in obese dysregulated patients with type 2 diabetes.”
BackgroundMethodInfluentialSelf-citationPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · cited 2×
“3%, respectively, after 26 weeks of treatment with liraglutide, both in combination with other glucose-lowering agents (metformin plus rosiglitazone or glimepiride).(24,25) Several possible explanations for the near-normalization of HbA1c after treatment with exercise plus liraglutide in the present study should be co…”
BackgroundResulton behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Research works printed but not linked: 19
- 10.2337/dc16-S007 · DOI
- 10.1620/tjem.227.289 · DOI · Paper page
- George CM, 2015, Management of blood glucose with noninsulin therapies in type 2 diabetes, Am Fam Physician, 92, 27
- 10.2337/diab.43.7.862 · DOI · Paper page
- 10.1016/j.molmed.2008.01.003 · DOI · Paper page
- 10.1097/00005650-199206000-00002 · DOI · Paper page
- Bablok W, 1988, A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III, J Clin Chem Clin Biochem Z Für Klin Chem Klin Biochem, 26, 783
- 10.1210/jc.2009-0921 · DOI · Paper page
- 10.2337/diab.43.4.535 · DOI · Paper page
- 10.1016/0167-0115(84)90005-3 · DOI
- 10.2337/diacare.21.12.2191 · DOI · Paper page
- 10.1007/s00125-012-2774-z · DOI · Paper page
- 10.1016/S0140-6736(10)60307-8 · DOI · Paper page
- 10.1038/ijo.2012.208 · DOI · Paper page
- 10.2337/diab.44.9.1010 · DOI · Paper page
- 10.1210/jc.2013-2232 · DOI · Paper page
- 10.1016/S0140-6736(13)62154-6 · DOI · Paper page
- Pessin JE, 2013, Adipokines mediate inflammation and insulin resistance, Front Endocrinol, 4, 71
- 10.1139/apnm-2016-0122 · DOI
Cited by
KANALEY, J. A., COLBERG, S. R., CORCORAN, M. H., MALIN, S. K., RODRIGUEZ, N. R., CRESPO, C. J., KIRWAN, J. P., & ZIERATH, J. R. (2022) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002800 · Cited by 931
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
Noone, J., Mucinski, J. M., DeLany, J. P., Sparks, L. M., & Goodpaster, B. H. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.025 · Cited by 128
Vosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97
Dong, Y., Carty, J., Goldstein, N., He, Z., Hwang, E., Chau, D., Wallace, B., Kabahizi, A., Lieu, L., Peng, Y., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101352 · Cited by 93
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65
Schmidt, P. H. S., Pasqualotto, E., dos Santos, H. V., de Souza, L. S. N., dos Santos, B. E., Chavez, M. P., Ferreira, R. O. M., Hohl, A., Ronsoni, M. F., & van de Sande-Lee, S. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.009 · Cited by 18
Endurance Training Improves GLP-1 Sensitivity and Glucose Tolerance in Overweight Women
Åkerström, T., Stolpe, M. N., Widmer, R., Dejgaard, T. F., Højberg, J. M., Møller, K., Hansen, J. S., Trinh, B., Holst, J. J., Thomsen, C., et al. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac111 · Cited by 15
Self-citation
Metadata
- Authors
- Mensberg, P., Nyby, S., Jørgensen, P. G., Storgaard, H., Jensen, M. T., Sivertsen, J., Holst, J. J., Kiens, B., Richter, E. A., Knop, F. K., & Vilsbøll, T.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-11-04
- Volume
- 19
- Issue
- 2
- Pages
- 172-180
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2527559853
- Cited by
- 69
- References
- 19
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Eli Lilly and Company
- Gentofte Hospital
- AstraZeneca
- Novartis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.